Teneligliptin
Overview[edit]
Teneligliptin is an oral antidiabetic medication used in the management of type 2 diabetes mellitus. It belongs to the class of drugs known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones, thereby enhancing the body's ability to lower blood glucose levels.
Mechanism of Action[edit]
Teneligliptin functions by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, teneligliptin prolongs the action of these hormones, leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner.
Pharmacokinetics[edit]
Teneligliptin is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It has a half-life of approximately 24 hours, allowing for once-daily dosing. The drug is primarily metabolized in the liver and excreted via the kidneys.
Clinical Use[edit]
Teneligliptin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin to achieve better glycemic control.
Side Effects[edit]
Common side effects of teneligliptin include nasopharyngitis, headache, and hypoglycemia when used in combination with other antidiabetic medications. Rare but serious side effects may include pancreatitis and allergic reactions.
Contraindications[edit]
Teneligliptin is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. Caution is advised in patients with severe renal impairment or hepatic impairment.
